Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
ClearPoint Neuro

ClearPoint Neuro (NASDAQ: CLPT) insider transactions

In the twelve months to 10 November 2026, executives and directors of ClearPoint Neuro reported 9 open-market sales of 151,243 shares ($2.5m) and 0 open-market purchases, by 4 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in ClearPoint Neuro shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
1 October 2026Fletcher R JohnDirectorGrant or award+993$12.21132,004Form 4
1 October 2026Richards Timothy T.DirectorGrant or award+319$12.2187,863Form 4
2 September 2026Burnett JosephCEO and PresidentOption exercise+12,517$3.47130,720Form 4
1 July 2026Richards Timothy T.DirectorGrant or award+222$17.8487,544Form 4
1 July 2026Fletcher R JohnDirectorGrant or award+662$17.84131,011Form 4
30 June 2026Burnett JosephCEO and PresidentGrant or award+1,361$11.93118,203Form 4
30 June 2026D'Alessandro DaniloChief Financial OfficerGrant or award+1,085$11.93103,769Form 4
30 June 2026Stigall L. JeremyChief Business OfficerGrant or award+1,781$11.93110,263Form 4
29 June 2026Burnett JosephCEO and PresidentOption exercise+20,000$2.50136,842Form 4
29 June 2026Burnett JosephCEO and PresidentOpen-market sale−20,000$19.38116,842Form 4
17 June 2026Burnett JosephCEO and PresidentOption exercise+60,000$2.50176,842Form 4
17 June 2026Burnett JosephCEO and PresidentOpen-market sale−60,000$17.79116,842Form 4
17 June 2026Burnett JosephCEO and PresidentOpen-market sale−1,843$17.94191,388Form 4
4 June 2026Richards Timothy T.DirectorOption exercise+500$10.0087,698Form 4
4 June 2026Richards Timothy T.DirectorShares withheld for tax−376$13.3087,322Form 4
1 June 2026Richards Timothy T.DirectorOpen-market sale−5,415$12.1787,198Form 4
21 May 2026Klein Matthew B.DirectorOpen-market sale−16,000$11.5946,935Form 4
20 May 2026Fallon Lynnette CDirectorOpen-market sale−5,091$11.1448,227Form 4
19 May 2026Liau Linda M.DirectorOption exercise+12,417—64,801Form 4
19 May 2026Girin Pascal E RDirectorOption exercise+12,417—110,623Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the ClearPoint Neuro page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.